Predictive Factors for Response and Toxicity in Chemotherapy: Pharmacogenomics

Seminars in Colon and Rectal Surgery

Volumn 19, Issue 4, 2008, Pages 226-230

  Sanoff, Hanna K ^a,b,c   McLeod, Howard L ^a,b,c  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; THYMIDYLATE SYNTHASE;

ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; CYTOPENIA; DIARRHEA; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; DRUG GLUCURONIDATION; DRUG TOLERABILITY; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; LIVER METASTASIS; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; PHARMACOGENOMICS; PREDICTION; SEPSIS; SURVIVAL RATE; SURVIVAL TIME; TANDEM REPEAT; THERAPY EFFECT; TREATMENT RESPONSE; WILD TYPE;

EID: 56349165203     PISSN: 10431489     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.scrs.2008.09.007     Document Type: Article

References (33)

1. Simmonds P.C. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321 7260 (2000) 531-535
2. Gill S., Loprinzi C.L., Sargent D.J., et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 22 10 (2004) 1797-1806
3. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 16 (2000) 2938-2947
4. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 13 (2000) 905-914
5. Fuchs C.S., Marshall J., Mitchell E., et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25 30 (2007) 4779-4786
6. Andre T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 23 (2004) 2343-2351
7. Nordlinger B., Sorbye H., Glimelius B., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 9617 (2008) 1007-1016
8. Heggie G.D., Sommadossi J.P., Cross D.S., et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47 8 (1987) 2203-2206
9. Takimoto C.H., Lu Z.H., Zhang R., et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 2 3 (1996) 477-481
10. Diasio R.B., Beavers T.L., and Carpenter J.T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81 1 (1988) 47-51
11. Tuchman M., Stoeckeler J.S., Kiang D.T., et al. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N Engl J Med 313 4 (1985) 245-249
12. Van Kuilenburg A.B., Meinsma R., Zoetekouw L., et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12 7 (2002) 555-558
13. Wei X., McLeod H.L., McMurrough J., et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 98 3 (1996) 610-615
14. Milano G., and Etienne M.C. Potential importance of dihydropyrimidine dehydrogenase (DPD) in cancer chemotherapy. Pharmacogenetics 4 6 (1994) 301-306
15. Yen J.L., and McLeod H.L. Should DPD analysis be required prior to prescribing fluoropyrimidines?. Eur J Cancer 43 6 (2007) 1011-1016
16. Van Kuilenburg A.B., Meinsma R., Zoetekouw L., et al. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer 101 3 (2002) 253-258
17. Ezzeldin H.H., Lee A.M., Mattison L.K., et al. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 11 24 Pt. 1 (2005) 8699-8705
18. Magne N., Etienne-Grimaldi M.C., Cals L., et al. Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br J Clin Pharmacol 64 2 (2007) 237-240
19. Gutheil J., and Finucane D. Antimetabolites. In: Perry M. (Ed). The Chemotherapy Source Book. ed 3 (2001), Lippincott Williams & Wilkins, Philadelphia, PA 208-227
20. Leichman C.G., Lenz H.J., Leichman L., et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15 10 (1997) 3223-3229
21. Lenz H.J., Leichman C.G., Danenberg K.D., et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14 1 (1996) 176-182
22. Johnston P.G., Lenz H.J., Leichman C.G., et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55 7 (1995) 1407-1412
23. Kawakami K., Omura K., Kanehira E., et al. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19 4B (1999) 3249-3252
24. Pullarkat S.T., Stoehlmacher J., Ghaderi V., et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogen J 1 1 (2001) 65-70
25. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 1 (2004) 23-30
26. Saltz L.B., Niedzwiecki D., Hollis D., et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 25 23 (2007) 3456-3461
27. Rothenberg M.L., Meropol N.J., Poplin E.A., et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 19 18 (2001) 3801-3807
28. Iyer L., Das S., Janisch L., et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogen J 2 1 (2002) 43-47
29. Innocenti F., Undevia S.D., Iyer L., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22 8 (2004) 1382-1388
30. Marcuello E., Altes A., Menoyo A., et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91 4 (2004) 678-682
31. Rouits E., Boisdron-Celle M., Dumont A., et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10 15 (2004) 5151-5159
32. Ando Y., Saka H., Ando M., et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60 24 (2000) 6921-6926
33. Hoskins J.M., Goldberg R.M., Qu P., et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99 17 (2007) 1290-1295